The Budget Blindside: Did Pharma Fight The Wrong Battle?
Executive Summary
The bigger 'Donut Hole' discount is a rare loss for pharma on Capitol Hill – one that may in part be because industry did too good a job fighting off a different drug pricing measure.
You may also be interested in...
Medicaid Rebates For Brands Could Rise $3.2Bn Over Next Decade Under New Law
Provision included in appropriations legislation directs manufacturers to calculate average prices for brands without including the cost of authorized generics, which will lead to higher rebates.
“Lame Duck” Congress Has High Stakes For Pharma Companies
Industry faces an uphill fight in a last-ditch effort to reverse the Medicare “donut hole” changes enacted at the start of 2018. At the same time, a stand-off over OTC monograph reform could have ripple effects on the plans to modernize the US FDA Office of New Drugs.
'Lame Duck' Congress Has High Stakes For Pharma Companies
Industry faces an uphill fight in a last-ditch effort to reverse the Medicare “donut hole” changes enacted at the start of 2018. At the same time, a stand-off over OTC monograph reform could have ripple effects on the plans to modernize the US FDA Office of New Drugs.